Citation
Miller DM, Buchbinder EI, Czapla JA, Emerick KS, Kaufman HL, Patel VA, Tsai KY, Wong MK. Authorship Begins Before the Byline. Journal of Cutaneous Oncology. 2026;4(2). doi:10.59449/joco.2026.10.28.
Research teams should be able to explain both why someone qualifies for authorship and how potentially substantial contributors were given a meaningful opportunity to engage.
Why this editorial matters
Authorship begins with the research question and the people brought in to answer it. By the time a manuscript is circulated, choices about design, data, interpretation, and whose expertise to seek have already shaped both the science and the possible byline.
The editorial grew out of a Society of Cutaneous Oncology workshop that brought clinicians, investigators, editors, and industry colleagues into the same conversation. The accompanying survey helped identify where expectations differ; the article develops a more focused argument about opportunity, contribution, credit, and accountability.
Opportunity is not automatic authorship
The clinician who generated the evidence
Clinical care may make a study possible without, by itself, settling authorship. When clinicians have contributed substantially, an early invitation into the analysis and interpretation can give them a genuine chance to qualify.
The expert invited late
Someone with no earlier role may still contribute meaningful scientific interpretation. A prominent name or a quick approval cannot replace substantive review, time to examine the evidence, and freedom to challenge the conclusions.
Among 35 respondents to a study-lead question, 26 (74%) favored offering clinicians whose care generated the data an opportunity to contribute further, while recognizing that clinical care alone is insufficient for authorship. These responses describe a small, self-selected community—not a general estimate of researchers’ views.
Apply the criteria across roles
Job title, payment, institutional rank, and site convention do not decide authorship. The article considers how clinical trial teams can recognize the scientific work of investigators, industry scientists, statisticians, medical communications professionals, and others while applying the same contribution and accountability criteria to each person.
It also asks what an invitation demands in practice: enough time to understand the work, review the evidence, contribute to interpretation, and accept responsibility for the published paper.
A process the team can explain
- Identify potential contributors and the work being requested early.
- Make clear what remains open to influence and what authorship requires.
- Revisit participation and proposed leading roles as contributions evolve.
- Explain author order and recognize meaningful work below the authorship threshold.
A byline records the outcome of collaboration. The conversations that make that outcome fair and defensible need to happen while the work can still change.
Authors
David Michael Miller, Elizabeth I. Buchbinder, Juliane Andrade Czapla, Kevin S. Emerick, Howard L. Kaufman, Vishal Anil Patel, Kenneth Y. Tsai, and Michael K. Wong.